ClinicalTrials.gg

TargetBeta

IL2

interleukin 2 · also IL-2, TCGF · Interleukins

7 programs in company-led studies act on IL2, from 5 companies: 2 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
daromunrulePhilogenphase 366 running–NCIt
darleukinrulePhilogenphase 395 running–NCIt
Daxokafusp AlfaSanofiphase 222 runningIL15, PDCD1a judged reading
SAR444336Sanofiphase 221 running–the company's pipeline
Anti-PD-1/IL-2 Fusion Protein TEV-56278Teva Pharmaceutical Industriesphase 122 runningPDCD1the company's pipeline
IL-2 Mutein/Fc Fusion Protein HM16390ruleHanmi Pharmaceuticalphase 111 running–NCIt
Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101ruleOutpace Biophase 110 runningEGFR, MSLNNCIt

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.